Bicara Therapeutics/$BCAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Ticker
$BCAX
Sector
Primary listing
Employees
55
Headquarters
Website
BCAX Metrics
BasicAdvanced
$634M
-
-$2.35
-
-
Price and volume
Market cap
$634M
52-week high
$28.09
52-week low
$7.80
Average daily volume
293K
Financial strength
Current ratio
25.796
Quick ratio
25.344
Long term debt to equity
0.267
Total debt to equity
0.514
Profitability
EBITDA (TTM)
-121.003
Effective tax rate (TTM)
-0.30%
Management effectiveness
Return on assets (TTM)
-22.85%
Return on equity (TTM)
-32.71%
Valuation
Price to book
1.46
Price to tangible book (TTM)
1.46
Price to free cash flow (TTM)
-5.024
Free cash flow yield (TTM)
-19.91%
Free cash flow per share (TTM)
-2.313
Growth
Earnings per share change (TTM)
-97.48%
Bulls say / Bears say
Bicara has begun dosing patients in its FORTIFI-HN01 pivotal Phase 2/3 trial evaluating ficerafusp alfa in combination with pembrolizumab for first-line recurrent or metastatic head and neck squamous cell carcinoma, marking a move into late-stage development.
Updated Phase 1/1b data presented at ASCO 2025 showed deep and durable responses with ficerafusp alfa plus pembrolizumab in HPV-negative recurrent/metastatic head and neck cancer, including a median duration of response of 21.7 months and median overall survival of 21.3 months.
With roughly $490 million in cash and cash equivalents as of December 31, 2024, Bicara possesses a strong balance sheet expected to fund operations through the first half of 2029, bolstering continued clinical progress.
Bicara’s pipeline is concentrated on a single lead asset, ficerafusp alfa, leaving the company vulnerable to binary clinical risk if this program does not succeed.
Even though dosing in the pivotal Phase 2/3 FORTIFI-HN01 trial started in February 2025, there is still no efficacy data available, creating considerable uncertainty for investors regarding trial outcomes.
In Q4 2024, Bicara posted a net loss of $20.96 million, highlighting a high cash burn that could strain the company’s cash runway if research and development costs keep climbing.
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicara Therapeutics stock?
Bicara Therapeutics (BCAX) has a market cap of $634M as of September 15, 2025.
What is the P/E ratio for Bicara Therapeutics stock?
The price to earnings (P/E) ratio for Bicara Therapeutics (BCAX) stock is 0 as of September 15, 2025.
Does Bicara Therapeutics stock pay dividends?
No, Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Bicara Therapeutics dividend payment date?
Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicara Therapeutics?
Bicara Therapeutics (BCAX) does not currently have a Beta indicator.